Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Nucl Med Commun. 2016 Feb;37(2):122–128. doi: 10.1097/MNM.0000000000000406

Table 1.

Baseline Demographics

Overall (N=24) Surviving
Participants
(N=16)
Deceased
Participants (N=8)
Age 54.25 ± 8.9 55.19 ± 6.46 52.38 ± 12.83
Sex
  Male 14 (58.33%) 10 (62.50%) 4 (50.00%)
  Female 10 (41.67%) 6 (37.50%) 4 (50.00%)
ECOG
  0 13 (54.17%) 12 (75.00%) 1 (12.50%)
  1 11 (45.83%) 4 (25.00%) 7 (87.50%)
Treatment
  Dabrafenib + trametinib 3 (12.50%) 2 (12.50%) 1 (12.50%)
  Vemurafenib + cobimetinib 21 (87.50%) 14 (87.50%) 7 (87.50%)